5-Amino-1MQ
Fat LossSmall Molecule / MetabolicExperimental
Small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor studied for NAD+ metabolism and body-composition research. Not an FDA-approved drug.
For research use only.
Key Facts
- CAS
- 42464-96-0
- Molecular Weight (MW)
- 286.11 g/mol
- Half-life
- 3.8-6.9 hours
- Unit
- mg
- Administration Route
- Oral
- Frequency
- 1-3x daily
- Last updated
- 8/23/2026
- Targets
- NNMTNAD+ salvage pathway
Overview
Small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor studied for NAD+ metabolism and body-composition research. Not an FDA-approved drug.
Protocol
- Dosage Range
- 50-150 mg per day, split doses
- Frequency
- 1-3x daily
- Cycle
- 4-12 weeks on, 4 weeks off
- Administration Route
- Oral
- Reconstitution Guide
- N/A (capsule form common)
Science
Mechanism of Action
Inhibits NNMT, which methylates nicotinamide and can deplete the NAD+ salvage pool. In rodent models this has been linked to higher cellular NAD+, altered adipocyte metabolism, and reduced fat mass.
Targets
NNMTNAD+ salvage pathway
Studies
- NNMT inhibition and adiposity in mice— Journal/year not available
Benefits
Metabolic research toolNAD+ pathway probeAdipose-biology models
Potential Side Effects
- Limited human safety data
- GI upset reported anecdotally
- Unknown long-term effects
References
- PubMed NNMT / 5-amino-1MQExternal link · Year —
- PubChem 5-Amino-1MQExternal link · Year —